Cite

HARVARD Citation

    Fizazi, K. et al. (n.d.). 791OUpdated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Annals of oncology. p. . [Online]. 
  
Back to record